中度大分割每日一次对比每日两次胸部放疗同步依托泊苷顺铂治疗局限期小细胞肺癌:多中心II期随机试验
这项多中心II期随机试验纳入182例局限期小细胞肺癌患者,比较每日两次45 Gy/30次与每日一次65 Gy/26次同步放化疗的疗效与毒性。
要点
- 两组总生存、≥3级食管炎、肺炎及治疗相关死亡无显著差异。
核心结论
- 在局限期小细胞肺癌中,中度大分割每日一次同步放化疗较每日两次方案改善无进展生存期且毒性相似。
研究设计与样本
- 多中心、II期、随机试验纳入182例18至75岁病理确诊局限期小细胞肺癌且ECOG体能状态0至1的患者。
- 患者接受4至6周期依托泊苷-顺铂化疗,随机分配至每日两次45 Gy/30次组(94例)或每日一次65 Gy/26次组(88例),同步放化疗于化疗第1至3周期开始。
- 主要终点为无进展生存期,治疗有效者接受预防性颅脑照射。
主要发现
- 2年无进展生存率分别为28.4%(95%CI 18.2-38.6)和42.3%(95%CI 31.1-53.5)。
关键数值与推荐
- 每日两次方案:45 Gy分30次;每日一次方案:65 Gy分26次,均同步依托泊苷-顺铂化疗。
临床怎么用
- 中度大分割每日一次同步放化疗可作为局限期小细胞肺癌的候选方案,但需警惕≥3级急性淋巴细胞减少。
- 该方案尚需III期随机试验进一步验证后方可改变临床实践。
局限性
- 本研究为II期随机试验,样本量有限,结论需III期试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Chemotherapy and concurrent thoracic radiation therapy (CCTRT) followed by prophylactic cranial irradiation (PCI) is the standard of care for limited-stage small cell lung cancer (LS-SCLC). We aimed to compare the efficacy and toxicity of moderately hypofractionated once-daily CCTRT with that of a standard twice-daily regimen. METHODS AND MATERIALS: This multicenter, phase 2, randomized study enrolled patients aged 18 to 75 years old who had pathologically confirmed LS-SCLC and an Eastern Cooperative Oncology Group performance status of 0 to 1. Eligible patients received 4 to 6 cycles of etoposide-cisplatin chemotherapy and were randomized to receive twice-daily CCTRT at 45 Gray (Gy) in 30 fractions or once-daily CCTRT at 65 Gy in 26 fractions, commencing with cycles 1 to 3 of chemotherapy. PCI was given to good responders. The primary endpoint was progression-free survival (PFS). RESULTS: The analyses included 182 patients, with 94 in the twice-daily group and 88 in the once-daily group. CCTRT started with cycle 3 of chemotherapy for most patients (80.2%). At a median follow-up of 24.3 months, the median PFS was 13.4 months (95% confidence interval [CI], 10.8-16.0) in the twice-daily group versus 17.2 months (95% CI, 11.8-22.6) in the once-daily group (P = .031), with 2-year PFS rates of 28.4% (95% CI, 18.2-38.6) and 42.3% (95% CI, 31.1-53.5), respectively. The estimated overall survival was 33.6 months in the twice-daily group versus 39.3 months in the once-daily group (P = .137). The median locoregional PFS was 23.9 months in the twice-daily group and was not reached in the once-daily group (P = .017). The incidences of most toxicities were similar in both groups, except for a higher incidence of ≥grade 3 acute lymphopenia in the once-daily group (71.7% vs 40.2% in the twice-daily group; P < .001). There was no difference in the incidences of ≥grade 3 esophagitis (17.4% vs 15.3%, respectively), pneumonitis (3.3% vs 2.4%, respectively) or treatment-related death (2.2% vs 1.2%, respectively) between the once-daily and twice-daily groups. CONCLUSIONS: Moderately hypofractionated, once-daily CCTRT showed improved PFS and similar toxicities compared with twice-daily CCTRT in LS-SCLC. This regimen should be evaluated for comparison in a phase 3 randomized trial.
引用
- Qiu B, Li Q, Liu J, et al. Moderately Hypofractionated Once-Daily Compared With Twice-Daily Thoracic Radiation Therapy Concurrently With Etoposide and Cisplatin in Limited-Stage Small Cell Lung Cancer: A Multicenter, Phase II, Randomized Trial. Int J Radiat Oncol Biol Phys. 2021. PMID: 33992717. doi:10.1016/j.ijrobp.2021.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。